Developing Innovative
Best-in-Class Vaccines

Computationally Designed VLP Vaccines

By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

RSV, hMPV, and SARS-CoV-2 Vaccines

Our vaccine candidates for respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.

Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.


In the News

Icosavax Appoints Thomas J. Russo Chief Financial Officer

Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst covering biotechnology, and in operations and vaccine manufacturing for a large pharma company.

Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate

First participants dosed in a Phase 1 clinical trial to assess safety and efficacy of IVX-411 with or without Seqirus Inc.’s proprietary adjuvant MF59® in subjects naïve to COVID-19

Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials

Company’s novel computationally designed virus-like particle (VLP) technology has the potential to create safe, effective, and durable vaccines against life-threatening respiratory viruses in older adults